Cancer News and Research

Latest Cancer News and Research

Heartburn can cause cancer: New guide for patients

Every day, an estimated 25 million American adults suffer from heartburn. Some experts believe that 40 percent of adults experience heartburn every month. Despite these staggering statistics, few people understand the real risk that Heartburn can cause Cancer.

6 Aug 2012

Diagnostic imaging in stage IV cancer on the rise

Diagnostic imaging in elderly patients with stage IV cancer has increased significantly in recent years, while its use among those with early-stage disease has decreased, suggest study findings.

6 Aug 2012

Wellcome Trust grants £1.6 million Translation Award for development of more effective radiotherapy

The Wellcome Trust has awarded a £1.6 million Translation Award to a research team led by the University of Lincoln to develop more effective radiotherapy treatment for thousands of cancer sufferers by providing unique monitoring and imaging for patients receiving proton therapy.

6 Aug 2012

New Translational Oncology Program at University of Michigan

The University of Michigan Comprehensive Cancer Center is harnessing its expertise in basic science research to speed the translation into clinical trials and new treatment opportunities for cancer patients.

6 Aug 2012

Mutations in Ras gene alone may not cause tumours

Despite a huge amount of research effort, the molecular mechanisms that underlie the transition from a "normal" cell to a cancerous cell are only poorly understood. After the discovery of the first cancer-causing genes or oncogenes and the finding that they are mutated forms of normal cellular genes, it was widely believed that a single mutation was enough to cause cancer.

6 Aug 2012

Human-derived breast cancer xenografts allow revolution in individualized cancer care

Cell cultures are homogeneous. Human tumors are not. A University of Colorado Cancer Center study recently published in the journal Breast Cancer Research and Treatment reports the development of human-derived estrogen-positive (ER+) breast cancer models that retain their heterogeneity, allowing researchers to more accurately test drugs for this disease.

6 Aug 2012

CPRIT awards $48.2 million in new grants to investigators at UT Southwestern Medical Center

The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded $48.2 million in new grants to investigators at UT Southwestern Medical Center to support cancer-related projects and to recruit pre-eminent cancer researchers.

6 Aug 2012

Previously uncharacterized protein dramatically influences inflammation

A UNC-led team of scientists describes the function of a previously uncharacterized protein that dramatically influences inflammation.

6 Aug 2012

Potential drug targets and prognostic markers for prostate cancer

Two proteins that act in opposing directions - one that promotes cancer and one that suppresses cancer - regulate the same set of genes in prostate cancer, Vanderbilt-Ingram Cancer Center researchers have found.

6 Aug 2012

Empa physicist analyzes structure and composition of soot particles

Since June 2012, it is official: The World Health Organisation (WHO) has classified diesel soot as a lung carcinogen. Artur Braun, a physicist at Empa and an X-ray spectroscopy expert, has made crucial contributions to analyzing the structure and composition of soot particles.

6 Aug 2012

Novel multireceptor-targeted somatostatin analogue found effective against neuroendocrine tumors

A researcher at Moffitt Cancer Center and his international team of colleagues have reported study results on a novel multireceptor-targeted somatostatin analogue called pasireotide (SOM230) manufactured by Novartis Pharma AG.

6 Aug 2012

New research center to expedite study of gene transfer approach

In an alliance aimed at bringing a new, personalized immunotherapy approach to patients with a wide variety of cancers, the University of Pennsylvania and Novartis announced today an exclusive global research and licensing agreement to further study and commercialize novel cellular immunotherapies using chimeric antigen receptor (CAR) technologies.

6 Aug 2012

Rexahn announces completion of RX-3117 exploratory Phase I clinical trial in cancer patients

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed its exploratory Phase I clinical trial of RX-3117 in cancer patients.

6 Aug 2012

NeoGenomics introduces new molecular assay that detects SF3B1 gene mutations

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today that it has validated and launched the first molecular assay for clinical use in the United States that detects mutations in the SF3B1 gene (splicing factor 3b, subunit 1).

6 Aug 2012

Nanobiotix, PharmaEngine partner to develop NBTXR3 for cancer

French Nanobiotix S.A. announced today that it entered into a strategic partnership with PharmaEngine, Inc. for the rapid development of NBTXR3, the lead product from the NanoXray pipeline of Nanobiotix.

6 Aug 2012

Nanobiotix, PharmaEngine partner to commercialize NBTXR3 for soft tissue sarcoma

PharmaEngine, Inc. announced today the execution of an exclusive license and collaboration agreement with France-based Nanobiotix S.A. for the development and commercialization of NBTXR3, currently being investigated in a phase I study with soft tissue sarcoma patients.

6 Aug 2012

TWi Pharmaceuticals completes AC-201 phase II study on type II diabetes

TWi Pharmaceuticals, Inc., a specialty pharmaceutical company based in Taiwan, today announced its fully owned subsidiary, TWi Biotechnology, Inc. has completed a multinational phase II dose-ranging study of AC-201, an orally available IL-1 Beta modulator, in 259 patients with type II diabetes uncontrolled on up to three oral medications.

6 Aug 2012

Clovis Oncology, Foundation Medicine enter diagnostic collaboration

Foundation Medicine, Inc. and Clovis Oncology, Inc. announced today that they have entered into a diagnostic collaboration.

6 Aug 2012

Scientists identify key factor that drives resistance to cancer drug

Developing resistance to chemotherapy is a nearly universal, ultimately lethal consequence for cancer patients with solid tumors - such as those of the breast, prostate, lung and colon - that have metastasized, or spread, throughout the body. A team of scientists led by Fred Hutchinson Cancer Research Center has discovered a key factor that drives this drug resistance - information that ultimately may be used to improve the effectiveness of therapy and buy precious time for patients with advanced cancer.

6 Aug 2012

Montefiore launches first fellowship program in Women's Physical Medicine and Rehabilitation

Montefiore Medical Center has launched the nation's first fellowship program in Women's Physical Medicine and Rehabilitation (WPM&R), and established a new clinical program in this specialty.

6 Aug 2012

Cancer News and Research

Latest Cancer News and Research

Heartburn can cause cancer: New guide for patients

Diagnostic imaging in stage IV cancer on the rise

Wellcome Trust grants £1.6 million Translation Award for development of more effective radiotherapy

New Translational Oncology Program at University of Michigan

Mutations in Ras gene alone may not cause tumours

Human-derived breast cancer xenografts allow revolution in individualized cancer care

CPRIT awards $48.2 million in new grants to investigators at UT Southwestern Medical Center

Previously uncharacterized protein dramatically influences inflammation

Potential drug targets and prognostic markers for prostate cancer

Empa physicist analyzes structure and composition of soot particles

Novel multireceptor-targeted somatostatin analogue found effective against neuroendocrine tumors

New research center to expedite study of gene transfer approach

Rexahn announces completion of RX-3117 exploratory Phase I clinical trial in cancer patients

NeoGenomics introduces new molecular assay that detects SF3B1 gene mutations

Nanobiotix, PharmaEngine partner to develop NBTXR3 for cancer

Nanobiotix, PharmaEngine partner to commercialize NBTXR3 for soft tissue sarcoma

TWi Pharmaceuticals completes AC-201 phase II study on type II diabetes

Clovis Oncology, Foundation Medicine enter diagnostic collaboration

Scientists identify key factor that drives resistance to cancer drug

Montefiore launches first fellowship program in Women's Physical Medicine and Rehabilitation

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in